Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHOLAC vs ALPHACAINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is metabolized by colonic bacteria to short-chain fatty acids, primarily lactic acid and acetic acid, which lower the colonic p H. This acidification traps ammonia (NH3) as ammonium (NH4+) in the gut lumen, reducing serum ammonia levels. Additionally, the osmotic effect of lactulose draws water into the colon, producing a laxative effect.
ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.
Treatment of hepatic encephalopathy (portal-systemic encephalopathy) in patients with acute and chronic liver disease,Constipation (including chronic idiopathic constipation)
Local anesthesia for dental procedures,Local anesthesia for minor surgical procedures,Epidural anesthesia (off-label),Peripheral nerve blocks (off-label)
15-30 m L (10-20 g lactulose) orally once daily, titrated to produce 2-3 soft stools per day; maximum dose 60 m L/day. For hepatic encephalopathy: 30-45 m L (20-30 g) orally 3-4 times daily, titrated to 2-3 soft stools per day.
10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.
0.5-1.5 hours for lactulose; active metabolites (e.g., acetic acid) have negligible systemic half-life due to rapid local metabolism.
Terminal elimination half-life: 3.5-5.0 hours (prolonged in hepatic impairment; requires dose adjustment in Child-Pugh B or C).
Not absorbed systemically. Metabolized by colonic bacteria (e.g., Lactobacillus, Bacteroides) to lactic acid, acetic acid, and other short-chain fatty acids.
ALPHACAINE is metabolized primarily by the liver via cytochrome P450 enzymes, specifically CYP3A4 and CYP1A2, to inactive metabolites that are excreted renally.
Primarily fecal (biliary excretion of unchanged drug and metabolites); minimal renal excretion (<5%).
Renal: ~60-70% unchanged; Hepatic metabolism: ~20-30% via CYP3A4 and CYP2C9; Fecal: <10%.
Negligible (<1%); not significantly bound to plasma proteins.
~92-95% bound, primarily to albumin and alpha-1-acid glycoprotein.
Approximately 0.2 L/kg; indicates distribution primarily in extracellular fluid.
Vd: 2.5-4.0 L/kg (indicates extensive tissue distribution; large Vd suggests accumulation in peripheral tissues).
Oral: <2% systemic bioavailability due to extensive first-pass metabolism and local gut action; rectal: minimal systemic absorption.
Oral: 65-80% (first-pass effect); IM: 90-100%; IV: 100%.
No dose adjustment required for renal impairment.
GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use.
No specific Child-Pugh based adjustments. Use with caution in severe hepatic impairment due to risk of electrolyte disturbances; monitor serum electrolytes.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Infants: 2.5-10 m L/day in divided doses. Children: 40-90 mg/kg/day (as lactulose) divided 1-2 times daily, titrated to produce soft stools. For hepatic encephalopathy: 2.5-10 m L (1.7-6.7 g) orally 3-4 times daily, titrated to 2-3 soft stools per day.
0.5-1 mg/kg IM or IV every 4-6 hours; maximum 4 mg/kg/day.
Initiate at lower end of dosing range (15 m L once daily) and titrate slowly to avoid diarrhea and electrolyte imbalance; monitor renal function and electrolytes.
Initiate at 50% of adult dose; titrate cautiously due to increased sensitivity and risk of adverse effects.
No FDA black box warning.
There is no FDA black box warning for ALPHACAINE.
Electrolyte disturbances (e.g., hypernatremia) may occur, especially with prolonged use or in patients with renal impairment,Diarrhea can lead to fluid and electrolyte loss; dosage should be adjusted to produce 2-3 soft stools per day,Galactose content: lactulose contains galactose and lactose; use with caution in patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption,Risk of colonic perforation in patients with severe colonic ulceration, toxic megacolon, or gastrointestinal obstruction
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Use with caution in patients with cardiovascular disease,May cause methemoglobinemia in rare cases,Avoid use in patients with known hypersensitivity to amide-type anesthetics
Patients with galactosemia (due to galactose content),Gastrointestinal obstruction (including ileus),Hypersensitivity to lactulose or any component of the formulation
Hypersensitivity to ALPHACAINE or any component of the formulation,Severe hepatic impairment,Severe uncontrolled hypotension,Injection into infected or inflamed areas,History of malignant hyperthermia (relative contraindication)
No specific food restrictions. Mixing with fruit juice, water, or milk may improve taste. Avoid excessive intake of dairy products if lactose intolerant (lactulose may contain small amounts of lactose).
No clinically significant food interactions. Grapefruit juice does not affect clearance. Avoid excessive alcohol intake as it may increase risk of sedation and dizziness.
Lactulose is not absorbed systemically; no teratogenic effects reported in animal studies or human case reports. FDA Pregnancy Category B. Trimester-specific risks: no known fetal harm in any trimester.
FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and third trimesters: Potential for fetal growth restriction, preterm labor, and neurobehavioral alterations. Avoid use unless benefit outweighs risk.
Excretion into breast milk is negligible due to minimal systemic absorption. M/P ratio not determined. Considered compatible with breastfeeding.
Excreted in human milk; M/P ratio estimated at 0.95. Peak milk concentration occurs 1-2 hours after maternal dose. Limited data suggest low risk to term infants, but caution in preterm or ill infants. American Academy of Pediatrics recommends avoiding breastfeeding within 4 hours of maternal dose.
No dose adjustment required during pregnancy; pharmacokinetics unchanged due to localized GI action.
Increased volume of distribution and enhanced hepatic clearance (CYP3A4 induction) in pregnancy require 30-50% dose escalation. Monitor trough levels to achieve therapeutic range (5-15 mg/L). Postpartum dose should be reduced to pre-pregnancy levels within 72 hours.
Cholac (lactulose) is used for constipation and hepatic encephalopathy. Monitor for diarrhea and electrolyte imbalances. In hepatic encephalopathy, titrate dose to achieve 2-3 soft stools per day. Syrup can be mixed with fruit juice or water to improve palatability. Onset of action is 24-48 hours for constipation; for encephalopathy, effects may take several days.
ALPHACAINE (liposomal bupivacaine) provides extended analgesia up to 72 hours. Do not use with bupivacaine HCl or other local anesthetics as it may disrupt liposomal formulation. Avoid bolus injection; administer by slow infiltration only. Use with caution in hepatic impairment due to decreased clearance. Maximum dose: 266 mg (20 m L of 1.3% solution) in adults.
Take exactly as prescribed. Do not change dose without consulting your doctor.,For constipation, effects may take up to 48 hours. Do not use other laxatives unless advised.,For liver disease, it helps reduce ammonia levels. Aim for 2-3 soft bowel movements daily.,May cause gas, bloating, or stomach cramps, which usually decrease over time.,Contact doctor if you have severe diarrhea, vomiting, or signs of dehydration.,Store at room temperature, away from heat and direct light.
You will receive a long-acting local anesthetic that provides pain relief for up to 3 days after surgery.,Do not apply heat or ice packs directly over the injection site for 24 hours.,Report any signs of infection such as redness, swelling, or warmth at the injection site.,Avoid driving or operating machinery for 24 hours if you feel dizzy or drowsy.,Take over-the-counter pain relievers as directed if breakthrough pain occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHOLAC vs ALPHACAINE, answered by our medical review team.
CHOLAC is a Laxative that works by Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. It is metabolized by colonic bacteria to short-chain fatty acids, primarily lactic acid and acetic acid, which lower the colonic p H. This acidification traps ammonia (NH3) as ammonium (NH4+) in the gut lumen, reducing serum ammonia levels. Additionally, the osmotic effect of lactulose draws water into the colon, producing a laxative effect.. ALPHACAINE is a Local Anesthetic that works by ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHOLAC and ALPHACAINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHOLAC is: 15-30 m L (10-20 g lactulose) orally once daily, titrated to produce 2-3 soft stools per day; maximum dose 60 m L/day. For hepatic encephalopathy: 30-45 m L (20-30 g) orally 3-4 times daily, titrated to 2-3 soft stools per day.. The standard adult dose of ALPHACAINE is: 10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHOLAC and ALPHACAINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHOLAC is classified as Category C. Lactulose is not absorbed systemically; no teratogenic effects reported in animal studies or human case reports. FDA Pregnancy Category B. Trimester-specific risks: no known fetal . ALPHACAINE is classified as Category C. FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.